Skip to main navigation Skip to search Skip to main content

Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression

  • Milad Ashrafizadeh
  • , Sepideh Mirzaei
  • , Mohammad Hossein Gholami
  • , Farid Hashemi
  • , Amirhossein Zabolian
  • , Mehdi Raei
  • , Kiavash Hushmandi
  • , Ali Zarrabi
  • , Nicolas H. Voelcker
  • , Amir Reza Aref
  • , Michael R. Hamblin
  • , Rajender S. Varma
  • , Saeed Samarghandian
  • , I. J. Arostegi
  • , M. Alzola
  • , Alan Prem Kumar
  • , Vijay Kumar Thakur
  • , Noushin Nabavi
  • , Pooyan Makvandi
  • , Franklin R. Tay
  • Gorka Orive
  • Sabanci University
  • Islamic Azad University
  • University of Tehran
  • Baqiyatallah Medical Sciences University
  • Monash University
  • CSIRO
  • Victorian Node of the Australian National Fabrication Facility
  • Harvard University
  • Xsphera Biosciences Inc.
  • Iran University of Medical Sciences
  • Palacký University Olomouc
  • Neyshabur University of Medical Sciences
  • University of the Basque Country
  • National University of Singapore
  • Scotland's Rural College
  • Shiv Nadar University
  • University of British Columbia
  • Italian Institute of Technology
  • Augusta University
  • Biomaterials and Nanomedicine (CIBER-BBN)
  • University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua)
  • NanoBioCel Research Group
  • Singapore National Eye Center

Research output: Contribution to journalReview articlepeer-review

161 Citations (Scopus)

Abstract

An important motivation for the use of nanomaterials and nanoarchitectures in cancer therapy emanates from the widespread emergence of drug resistance. Although doxorubicin (DOX) induces cell cycle arrest and DNA damage by suppressing topoisomerase activity, resistance to DOX has severely restricted its anti-cancer potential. Hyaluronic acid (HA) has been extensively utilized for synthesizing nanoparticles as it interacts with CD44 expressed on the surface of cancer cells. Cancer cells can take up HA-modified nanoparticles through receptor-mediated endocytosis. Various types of nanostructures such as carbon nanomaterials, lipid nanoparticles and polymeric nanocarriers have been modified with HA to enhance the delivery of DOX to cancer cells. Hyaluronic acid-based advanced materials provide a platform for the co-delivery of genes and drugs along with DOX to enhance the efficacy of anti-cancer therapy and overcome chemoresistance. In the present review, the potential methods and application of HA-modified nanostructures for DOX delivery in anti-cancer therapy are discussed.

Original languageEnglish
Article number118491
JournalCarbohydrate Polymers
Volume272
DOIs
Publication statusPublished - 15 Nov 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CD44
  • Doxorubicin
  • Drug resistance
  • Endocytosis
  • Hyaluronic acid
  • Nanodelivery system
  • Theranostic

ASJC Scopus subject areas

  • Organic Chemistry
  • Polymers and Plastics
  • Materials Chemistry

Fingerprint

Dive into the research topics of 'Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression'. Together they form a unique fingerprint.

Cite this